Expanding the Benefit: Dabrafenib/Trametinib as Tissue-Agnostic Therapy for BRAF V600E–Positive Adult and Pediatric Solid Tumors
The recent US Food and Drug Administration (FDA) approval of the dabrafenib/trametinib
combination as a tissue-agnostic treatment for solid tumors with BRAF V600E mutation is the …
combination as a tissue-agnostic treatment for solid tumors with BRAF V600E mutation is the …
BRAF—A tumour-agnostic drug target with lineage-specific dependencies
In June 2022, the FDA granted Accelerated Approval to the BRAF inhibitor dabrafenib in
combination with the MEK inhibitor trametinib for the treatment of adult and paediatric …
combination with the MEK inhibitor trametinib for the treatment of adult and paediatric …
Non–small cell lung cancer, version 3.2022, NCCN clinical practice guidelines in oncology
NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Non–Small Cell
Lung Cancer (NSCLC) provide recommended management for patients with NSCLC …
Lung Cancer (NSCLC) provide recommended management for patients with NSCLC …
Oncogene-addicted metastatic non-small-cell lung cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up☆
LE Hendriks, KM Kerr, J Menis, TS Mok… - Annals of …, 2023 - annalsofoncology.org
Details on diagnostic procedures are covered in the Supplementary Material Section 2,
available at https://doi. org/10.1016/j. annonc. 2022.12. 009. See Supplementary Figure S1 …
available at https://doi. org/10.1016/j. annonc. 2022.12. 009. See Supplementary Figure S1 …
Dabrafenib plus trametinib in BRAFV600E-mutated rare cancers: the phase 2 ROAR trial
V Subbiah, RJ Kreitman, ZA Wainberg, A Gazzah… - Nature medicine, 2023 - nature.com
BRAFV600E alterations are prevalent across multiple tumors. Here we present final efficacy
and safety results of a phase 2 basket trial of dabrafenib (BRAF kinase inhibitor) plus …
and safety results of a phase 2 basket trial of dabrafenib (BRAF kinase inhibitor) plus …
Phase II, Open-Label Study of Encorafenib Plus Binimetinib in Patients With BRAFV600-Mutant Metastatic Non–Small-Cell Lung Cancer
PURPOSE The combination of encorafenib (BRAF inhibitor) plus binimetinib (MEK inhibitor)
has demonstrated clinical efficacy with an acceptable safety profile in patients with BRAF …
has demonstrated clinical efficacy with an acceptable safety profile in patients with BRAF …
Tumor-agnostic precision medicine from the AACR GENIE database: clinical implications
Biomarker-driven cancer therapy has revolutionized precision oncology. With a better
understanding of tumor biology, tissue-agnostic targets have been characterized and …
understanding of tumor biology, tissue-agnostic targets have been characterized and …
[HTML][HTML] Precision oncology for BRAF-mutant cancers with BRAF and MEK inhibitors: from melanoma to tissue-agnostic therapy
Highlights•BRAF alterations lead to unbridled activation of the MAPK pathway which can
result in cancer development and progression.•BRAF and MEK inhibitors led to paradigm …
result in cancer development and progression.•BRAF and MEK inhibitors led to paradigm …
Emerging targeted therapies in advanced non-small-cell lung cancer
S Li, GS de Camargo Correia, J Wang, R Manochakian… - Cancers, 2023 - mdpi.com
Simple Summary The discovery of actionable oncogenic driver mutations in non-small-cell
lung cancer (NSCLC) has revolutionized the treatment and prognosis of this dreadful …
lung cancer (NSCLC) has revolutionized the treatment and prognosis of this dreadful …
BRAF-mutated non-small cell lung cancer: current treatment status and future perspective
N Yan, S Guo, H Zhang, Z Zhang, S Shen, X Li - Frontiers in oncology, 2022 - frontiersin.org
V-Raf murine sarcoma viral oncogene homolog B (BRAF) kinase, which was encoded by
BRAF gene, plays critical roles in cell signaling, growth, and survival. Mutations in BRAF …
BRAF gene, plays critical roles in cell signaling, growth, and survival. Mutations in BRAF …